Summary
Hormone responsive breast cancer is usually determined by the presence of estrogen receptors (ER) or progesterone receptors (PR) on primary invasive breast cancers. Adjuvant and metastatic hormone therapy are recommended based on primary ER and PR determination. Little information is available to determine if primary hormone receptors correlate with metastatic disease and if survival is influenced by metastatic receptor status. We retrospectively compared primary to metastatic tumor ER and PR content from 200 metastatic breast cancer patients. ER and PR analyses were available in both primary and metastatic disease in 200 and 173 patients, respectively. There was a correlation between both the ER and PR in the primary and metastatic lesion (p < 0.001). However, in 60 of 200 (30%) patients, discordance between primary and metastatic ER was noted. Tumors from 68 of 173 (39.3%) showed discordance for PR. In 39 (19.5%) patients, the ER primary status was positive and metastatic status was negative and in 21 (10.5%) patients, the primary status was negative and metastatic status was positive. Survival from the time of metastatic diagnosis was calculated. Those patients with ER positive primary and metastatic tumors (Positive/Positive) or only the metastatic lesion (Negative/Positive) had similar median survival (1131 and 1111 days, respectively). However, patients with tumors that changed from positive primary to negative metastasis (Positive/Negative) experienced significantly shorter median survival (669 days, p < 0.05). Likewise, median survival (580 days) was significantly shorter for patients with primary and metastasis ER negative (Negative/Negative, p < 0.001) compared to Positive/Positive (p < 0.001) or compared to Negative/Positive (p < 0.02). The changes in PR status were not associated with a change in survival. We found a significant discordance between hormone receptor content of primary versus metastatic breast cancer. The ER status of the metastatic lesion was a better predictor of survival. Therefore, optimal metastatic treatment cannot be determined solely on primary ER and PR analysis.
Similar content being viewed by others
References
AU Buzdar G Hortobagyi (1998) ArticleTitleUpdate on endocrine therapy for breastcancer Clin Cancer Res 4 IssueID3 527–534
CK Osborne MG Yochmowitz WA Knight SuffixIII WL McGuire (1980) ArticleTitleThe value of estrogen and progesterone receptors in the treatment of breast cancer Cancer 46 IssueID12 Suppl 2884–2888
InstitutionalAuthorNameEarly Breast Cancer Trialists Collaborative Group (1998) ArticleTitleTamoxifen for early breast cancer:an overview of the randomized trials.Early Breast Cancer Collaborative Group. Lancet 351 1451–1467
RM Elledge SAW Fuqua (2000) Estrogen and progesterone receptors JR Harris ME Lippman M Morrow CK Osborne (Eds) Diseases of the Breast Lippincott Williams & Wilkens Philadelphia 471–488
H Mouridsen M Gershanovich Y Sun et al. (2003) ArticleTitlePhase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 IssueID11 2101–2109
JM Nabholtz J Bonneterre A Buzdar JF Robertson B Thurliman (2003) ArticleTitleAnastrozole (Arimidex) versus tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results Eur J Cancer 39 IssueID12 1684–1689 Occurrence Handle10.1016/S0959-8049(03)00326-5 Occurrence Handle1:CAS:528:DC%2BD3sXlvVCntbg%3D Occurrence Handle12888362
JR DelaHaba-Rodriguez BM Ruiz EA Gomez et al. (2004) ArticleTitleComparative study of the immunohistochemical phenotype in breast cancer and its lymph node metastatic location Cancer Invest 22 IssueID2 219–224
GN Hortobagyi (2003) ArticleTitleFuture directions in the endocrine therapy of breast cancer Breast Cancer Res Treat 80 1 S37–S39
EE Lower RS Franco MA Miller OJ Martelo (1993) ArticleTitleEnzymatic and immunohistochemical evaluation of tyrosine phosphorylation in breast cancer specimens Breast Cancer Res Treat 26 IssueID3 217–224
DC Allred JM Harvey M Berardo GM Clark (1998) ArticleTitlePrognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 IssueID2 155–168
EE Lower R Blau P Gazder DL Stahl (1999) ArticleTitleThe effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer Breast Cancer Res Treat 58 IssueID3 205–211
M Hollander DA Wolfe (Eds) (1999) Nonparametric Statistical Methods EditionNumber2 Wiley New York
RW Blamey (2002) ArticleTitleGuidelines on endocrine therapy of breast cancer EUSOMA Eur J Cancer 38 IssueID5 615–634
FC Campbell RW Blamey CW Elston et al. (1981) ArticleTitleQuantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy Lancet 2 IssueID8259 1317–1319
JM Raemaekers LV Beex GF Pieters et al. (1987) ArticleTitle Progesterone receptor activity and the response to the first endocrine therapy in advanced breast cancer Eur J Cancer Clin Oncol 23 IssueID4 443–448
CK Osborne (1985) ArticleTitleHeterogeneity in hormone receptor status in primary and metastatic breast cancer Semin Oncol 12 IssueID3 317–326
WD Tilley DD Keightley EL Cant (1978) ArticleTitleInter-site variation of oestrogen receptors in human breast cancers Br J Cancer 38 IssueID4 544–546
BW Davis DT Zava GW Locher A Goldhirsch WH Hartmann (1984) ArticleTitleReceptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor Eur J Cancer Clin Oncol 20 IssueID3 375–382
DT Kiang BJ Kennedy (1977) ArticleTitleFactors affecting estrogen receptors in breast cancer Cancer 40 IssueID4 1571–1576
GE Gross GM Clark GC Chamness WL McGuire (1984) ArticleTitleMultiple progesterone receptor assays in human breast cancer Cancer Res 44 IssueID2 836–840
DF Hull SuffixIII GM Clark CK Osborne et al. (1983) ArticleTitleMultiple estrogen receptor assays in human breast cancer Cancer Res 43 IssueID1 413–416
RA Hawkins R Black RJC Steele JMJ Dixon AP McEwan Forest (1981) ArticleTitleOestrogen receptor concentration in primary breast cancer and axillary node metastases Breast Cancer Res Treat 1 245–251
R Hahnel E Twaddle (1985) ArticleTitleThe relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinomas Breast Cancer Res Treat 5 IssueID2 155–163
BD Li A Byskosh A Molteni RB Duda (1994) ArticleTitleEstrogen and progesterone receptor concordance between primary and recurrent breast cancer J Surg Oncol 57 IssueID2 71–77
T Mori T Morimoto K Komaki Y Monden (1991) ArticleTitleComparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer Cancer 68 IssueID3 532–537
T Kuukasjarvi J Kononen H Helin K Holli J Isola (1996) ArticleTitleLoss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy J Clin Oncol 14 IssueID9 2584–2589
C Kamby BB Rasmussen B Kristensen (1989) ArticleTitleOestrogen receptor status of primary breast carcinomas and their metastases relation to pattern of spread and survival after recurrence. Br J Cancer 60 IssueID2 252–257
H Mouridsen M Gershanovich (2003) ArticleTitleThe role of aromatase inhibitors in the treatment of metastatic breast cancer Semin Oncol 30 IssueID4 Suppl 14 33–45
PF Bross A Baird G Chen et al. (2003) ArticleTitleFulvestrant in postmenopausal women with advanced breast cancer Clin Cancer Res 9 IssueID12 4309–4317
Y Sekido S Umemura S Takekoshi et al. (2003) ArticleTitleHeterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation Int J Oncol 22 IssueID6 1225–1232
WQ Zheng J Lu JM Zheng FX Hu CR Ni (2001) ArticleTitleVariation of ER status between primary and metastatic breast cancer and relationship to p53 expression Steroids 66 IssueID12 905–910
TA Hopp SA Fuqua (1998) ArticleTitleEstrogen receptor variants J Mammary Gland Biol Neoplasia 3 IssueID1 73–83
Y Umekita Y Sagara H Yoshida (1998) ArticleTitleEstrogen receptor mutations and changes in estrogen receptor and progesterone receptor protein expression in metastatic or recurrent breast cancer Jpn J Cancer Res 89 IssueID1 27–32
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lower, E.E., Glass, E.L., Bradley, D.A. et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 90, 65–70 (2005). https://doi.org/10.1007/s10549-004-2756-z
Issue Date:
DOI: https://doi.org/10.1007/s10549-004-2756-z